Finally, antagonistic TNFR2 antibodies could reduce soluble TNFR2 secretion more potently than in Tregs from healthy donors, suggesting that these antibodies may preferentially target the tumor microenvironment [129]. This evidence concerns the gene TNFRSF1B and neoplasm.